The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis,” published in the January 2025 issue of Psychiatry by Kamp et al.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of interest in everyday activities, appetite changes, sleep disturbances and, in extreme cases,

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for the MM120 program in GAD,

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet Psychiatry.

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural alterations in the brains of people with bipolar disorder (BD), a chronic mental illness with one of the highest rates of attempted suicide — and for which no biological tools currently exist to guide diagnosis or treatment.

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

A team of US-based scientists have found "a probable causal connection" between a form of bacteria found in the human gut and the onset of depression.Carried out by a team from Harvard University and Massachusetts General Hospital,